India, April 14 -- Johnson & Johnson (JNJ) reported first-quarter 2026 results on Tuesday, reflecting a decline in earnings despite 9.9% worldwide revenue growth. In addition, the firm raised its revenue guidance for the midpoint of 2026.
For the first quarter, earnings slipped 52.4% to $5.24 billion from $10.99 billion in the prior year. On a per-share basis, earnings slipped to $2.14 from $4.54 an year ago.
Adjusted net earnings slipped to $6.61 billion or $2.70 per share from $6.71 billion or $2.77 in the prior year.
Net sales improved 9.9% to $24.06 billion from $21.89 billion a year ago.
Also, the firm noted the revenue growth was driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA in Immuno...